DBV Technologies SA
OTC:DBVTF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (109.5), the stock would be worth $2.9 (33% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 162.4 | $4.3 |
0%
|
| 3-Year Average | 109.5 | $2.9 |
-33%
|
| 5-Year Average | 115.8 | $3.07 |
-29%
|
| Industry Average | 10.7 | $0.28 |
-93%
|
| Country Average | 1.4 | $0.04 |
-99%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$852.8m
|
/ |
Jan 2026
$5.6m
|
= |
|
|
$852.8m
|
/ |
Dec 2026
$7.6m
|
= |
|
|
$852.8m
|
/ |
Dec 2027
$187.3m
|
= |
|
|
$852.8m
|
/ |
Dec 2028
$608.2m
|
= |
|
|
$852.8m
|
/ |
Dec 2029
$632.9m
|
= |
|
|
$852.8m
|
/ |
Dec 2030
$960.5m
|
= |
|
|
$852.8m
|
/ |
Dec 2031
$1.3B
|
= |
|
|
$852.8m
|
/ |
Dec 2032
$1.7B
|
= |
|
|
$852.8m
|
/ |
Dec 2033
$2.2B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| FR |
|
DBV Technologies SA
OTC:DBVTF
|
944.7m USD | 162.4 | -7.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 6.7 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 6.2 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 4 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 10.5 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 3.4 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.4 |
| 70th Percentile | 2.8 |
| Max | 29 441 857.7 |
Other Multiples
DBV Technologies SA
Glance View
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
